This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Legend Biotech (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
What Makes Legend Biotech (LEGN) a New Buy Stock
by Zacks Equity Research
Legend Biotech (LEGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think Legend Biotech (LEGN) Could Surge 135.16%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 135.2% upside potential for Legend Biotech (LEGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last?
by Zacks Equity Research
Legend Biotech (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Pacira (PCRX) Surges 14.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Pacira (PCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Company News for Mar 12, 2025
by Zacks Equity Research
Companies in The News Are: FRG, ORCL, LEGN, PAY
Compared to Estimates, Legend Biotech (LEGN) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Legend Biotech (LEGN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Strength Seen in Eton Pharmaceuticals (ETON): Can Its 10.8% Jump Turn into More Strength?
by Zacks Equity Research
Eton Pharmaceuticals (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Legend Biotech (LEGN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Legend Biotech (LEGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Novavax to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
On NVAX's third-quarter earnings call, investors will likely seek updates on management???s ongoing discussions with the FDA to remove the clinical hold on its two vaccine programs.
Viatris to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
VTRS' Q3 results are likely to gain from new product launches in all major geographies.
Gilead Science to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on GILD???s HIV franchise performance and oncology sales when the company reports third-quarter 2024 results.
Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Legend Biotech (LEGN) points to a 90.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Mortgage Rates Fall to a 12-Month Low
by Zacks Equity Research
Mortgage Rates Fall to a 12-Month Low.
Pre-Markets in Red to Close an Eventful Week, Earnings Mixed
by Zacks Equity Research
Pre-Markets in Red to Close an Eventful Week, Earnings Mixed.
Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid
by Zacks Equity Research
A third-party article suggests that Legend Biotech (LEGN) hired investment banking firm Centerview Partners to help its board review the takeover offer.
Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Legend Biotech (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Should You Buy Legend Biotech (LEGN) Ahead of Earnings?
by Zacks Equity Research
Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma
by Zacks Equity Research
Following the label expansion, J&J's (JNJ) Carvykti is approved as a second-line treatment for adults with relapsed/refractory myeloma. It was initially approved for use as a fifth- or later-line treatment.
Why Legend Biotech (LEGN) Stock Might be a Great Pick
by Kaibalya Pravo Dey
Legend Biotech (LEGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Company News for Mar 12, 2024
by Zacks Equity Research
Companies in The News Are: LEGN, BA, ALK, FTRE, AVGO.
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
by Zacks Equity Research
Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys are part of the Zacks top Analyst Blog.
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
by Nalak Das
We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.